Leaderboards/Statistical Methods in Clinical Trials

Statistical Methods in Clinical Trials

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Veronika Skrivankova
University of Bern
2
Anne de Hond
University Medical Center Utrecht
3
Ruishan Liu
National Centre for Infectious Diseases
4
Roemer J. Janse
Leiden University Medical Center
5
Ardalan Mirzaei
The University of Sydney
6
Natesh Singh
Evotec (United States)
7
Haidong Lu
Yale University
8
Camila Paola Malkewitz
Johannes Gutenberg University Mainz
9
Samar Abd ElHafeez
Alexandria University
10
Maximilian Maier
University College London

Rising Stars Papers

1
Predicting Depression Risk in Patients With Cancer Using Multimodal Data: Algorithm Development Study
JMIR Medical Informatics|2024
25 cit.
2
Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients
Cell Reports Medicine|2024
20 cit.
3
Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia
Clinical Infectious Diseases|2024
18 cit.
4
Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry
Nephrology Dialysis Transplantation|2024
17 cit.
5
Revisiting and Rethinking the Identifiable Victim Effect: Replication and Extension of Small, Loewenstein, and Slovic (2007)
Collabra Psychology|2024
13 cit.
6
The evolution of selection bias in the recent epidemiologic literature—a selective overview
American Journal of Epidemiology|2024
12 cit.
7
The intention of Egyptian healthcare workers to take the monkeypox vaccine: is urgent action required?
BMC Health Services Research|2024
9 cit.
8
Fusion event mediated by IS903B between chromosome and plasmid in two MCR-9- and KPC-2-co-producing Klebsiella pneumoniae isolates
Drug Resistance Updates|2024
8 cit.
9
Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers
Nature Communications|2024
7 cit.
10
When impact trials are not feasible: alternatives to study the impact of prediction models on clinical practice
Nephrology Dialysis Transplantation|2024
6 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Ewa Tomczak
Adam Mickiewicz University in Poznań
2
Katrina J. Scurrah
The University of Melbourne
3
Jacob F. Degner
AbbVie (United States)
4
Lucas Janson
Harvard University
5
Mathias Ambühl
TK Consult (Switzerland)
6
Manuela Ott
Swiss National Science Foundation
7
Olga Demler
Harvard University
8
Patrick R. Blackburn
St. Jude Children's Research Hospital
9
Ryan Copping
Acentech (United States)
10
Yuching Yang
United States Food and Drug Administration

Emerging Leaders Papers

1
Tailoring Risk Prediction Models to Local Populations
JAMA Cardiology|2024
25 cit.
2
Testing goodness-of-fit and conditional independence with approximate co-sufficient sampling
The Annals of Statistics|2022
13 cit.
3
Directionality and lexical selection in professional translators: Evidence from verbal fluency and translation tasks
The International Journal of Translation and Interpreting Research|2022
10 cit.
4
Loss‐of‐Function Variants in <scp><i>CUL3</i></scp> Cause a Syndromic Neurodevelopmental Disorder
Annals of Neurology|2024
10 cit.
5
Clinical and genomic characterization of an <scp>ATRA</scp>‐insensitive acute promyelocytic leukemia variant with a <i>FNDC3B::RARB</i> fusion
Genes Chromosomes and Cancer|2023
5 cit.
6
Pediatric Erythroid Sarcoma Diagnostically Confirmed by Identification of a Recurrent <scp><i>NFIA::CBFA2T3</i></scp> Fusion
Genes Chromosomes and Cancer|2024
5 cit.
7
Evaluation of Bayesian point-based system on the variant classification of hereditary cancer predisposition genes
Genetics in Medicine|2024
5 cit.
8
Abstract P021: Performance Of Pooled Cohort Equations And MESA Risk Score Across Race/Ethnicity And Socioeconomic Status To Estimate 10-year Cardiovascular Risk In Diverse New England Cohort
Circulation|2022
4 cit.
9
Three trajectories of gestational weight gain identified in an Australian twin study
European Journal of Obstetrics & Gynecology and Reproductive Biology|2022
3 cit.
10
Using Machine Learning to Test Causal Hypotheses in Conjoint Analysis
Political Analysis|2024
3 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Nan M. Laird
Yale University
2
Douglas G. Altman
Unknown
3
Daniel Yekutieli
Tel Aviv University
4
Angela Wood
University of Cambridge
5
Virgil L. Sheets
Indiana State University
6
David Moher
University of Ottawa
7
Jason Williams
Dalhousie University
8
A. E. Ades
University of Bristol
9
Matthias Egger
University of Zurich
10
Andrew P. Holmes
Birmingham City University

Current Senior Leaders Papers

1
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
BMJ|2021
95k cit.
2
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
BMJ|2009
83.3k cit.
3
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
PLoS Medicine|2009
64.1k cit.
4
Bias in meta-analysis detected by a simple, graphical test
BMJ|1997
56.3k cit.
5
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
PubMed|2009
45.1k cit.
6
Meta-analysis in clinical trials
Controlled Clinical Trials|1986
39.3k cit.
7
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Annals of Internal Medicine|2009
37.9k cit.
8
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Journal of Clinical Epidemiology|2009
19.9k cit.
9
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
BMC Medicine|2010
13.5k cit.
10
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Systematic Reviews|2021
13.5k cit.

Reagents for Statistical Methods in Clinical Trials

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

CTCF (D1A7) Rabbit Monoclonal Antibody

#3417$175,384
View Evidence →
Cell Signaling TechnologyEvidence 66

PKC-delta Antibody

#2058$317
View Evidence →